Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLOD2 | O00469 | 3/20 | 0.40 |
| ▸ | PLOD3 | O60568 | 2/20 | 0.39 |
| ▸ | PLOD1 | Q02809 | 2/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 8/20 | 0.37 |
| ▸ | CES1 | P23141 | 6/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL183178 | 0.81 | PLOD2 (0.46) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| SCHEMBL6517983 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| SCHEMBL6520648 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| Water SCHEMBL7197275 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| SCHEMBL9283764 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| SCHEMBL7213763 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| SCHEMBL31182132 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| Water SCHEMBL7191917 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| SCHEMBL9326020 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH | |
| SCHEMBL31622638 | 0.78 | PLOD2 (0.44) | PLOD2PLOD3PLOD1HDAC6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274295-B1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| CN-102015682-B | 3, 4-substituted piperidine derivatives as renin inhibitors | MERCK FROSST CANADA LTD | 2014-07-16 | — | — | CN | disclosed |
| CN-102015682-A | 3, 4-substituted piperidine derivatives as renin inhibitors | MERCK FROSST CANADA LTD | 2011-04-13 | — | — | CN | disclosed |
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2274295-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009135299-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-12 | — | — | WO | disclosed |
| CN-1328261-C | Uracil compounds and their use | SUMITOMO CHEMICAL CO (JP) | 2007-07-25 | — | — | CN | disclosed |
| CN-1636981-A | Uracil compounds and their use | SUMITOMO CHEMICAL CO (JP) | 2005-07-13 | — | — | CN | disclosed |
| CN-1204137-C | Uracil compound and application thereof | SUMITOMO CHEMICAL CO (JP) | 2005-06-01 | — | — | CN | disclosed |
| CN-1316426-A | Uracil compound and application thereof | SUMITOMO CHEMICAL CO (JP) | 2001-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, ACE2 | PLOD2 748/4885PLOD3 1208/4885PLOD1 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.